Adipocytokines as mediators of metabolic role of adipose tissue;Adipocitokini Kao Posrednici Metaboličke Uloge Masnog Tkiva

Acta Medica Croatica

Volumn 64, Issue 4, 2010, Pages 253-262

  Jakšić, V Pandžić ^a  

^a University of Zagreb School of Medicine   (Croatia)

Author keywords

Adiponectin; Adypocytokines; Binding protein 4; Interleukin 6; Leptin; Monocyte chemoattractant protein 1; Obesity; Plasminogen activator inhibitor 1; Resistin; Retinol; Tumor necrosis factor ; Visfatin

Indexed keywords

ADIPOCYTOKINE;

ADIPOSE TISSUE; ANIMAL; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; HUMANS;

EID: 79960094411     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-19.
2. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005; 19: 525-46. (Pubitemid 41819217)
3. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-32.
4. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444: 847-53. (Pubitemid 46024991)
5. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007; 3: 716- 24. (Pubitemid 350187017)
6. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32. (Pubitemid 24365442)
7. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004; 10: 563-9. (Pubitemid 38796839)
8. Cnop M, Landchild MJ, Vidal J i sur. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005-15. (Pubitemid 34438343)
9. Farooqi IS, Matarese G, Lord GM i sur. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110: 1093- 1103. (Pubitemid 35215890)
10. Hofbauer KG. Molecular pathways to obesity. Int J Obes Relat Metab Disord 2002; 26 Suppl 2: 18-27.
11. Saper CB, Chou TC, Elmquist JK. The need to feed: homeostatic and hedonic control of eating. Neuron 2002; 36: 199-211. (Pubitemid 35217887)
12. Woods SC, Benoit SC, Clegg DJ, Seeley RJ. Clinical endocrinology and metabolism. Regulation of energy homeostasis by peripheral signals. Best Pract Res Clin Endocrinol Metab 2004; 18: 497-515. (Pubitemid 39481230)
13. Enriori PJ, Evans AE, Sinnayah P, Cowley MA. Leptin resistance and obesity. Obesity (Silver Spring) 2006; 14 Suppl 5: 254-8.
14. DelParigi A, Chen K, Salbe AD i sur. Successful dieters have increased neural activity in cortical areas involved in the control of behavior. Int J Obes (Lond) 2007; 31: 440-8.
15. Bray GA, Champagne CM. Beyond energy balance: there is more to obesity than kilocalories. J Am Diet Assoc 2005; 105(5 Suppl 1): 17-23.
16. Friedman JM. Obesity in the new millennium. Nature 2000; 404: 632-34. (Pubitemid 30205067)
17. Chan JL, Mantzoros CS. Role of leptin in energydeprivation states: normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005; 366: 74-85. (Pubitemid 40956533)
18. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772-83. (Pubitemid 44453463)
19. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol 2004; 4: 371-9. (Pubitemid 38649279)
20. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998; 394: 897-901. (Pubitemid 28410912)
21. Otero M, Lago R, Gomez R i sur. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-1201. (Pubitemid 44277396)
22. Beltowski J, Wojcicka G, Jamroz A. Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. Atherosclerosis 2003; 170: 21-9. (Pubitemid 37086705)
23. Ciccone M, Vettor R, Pannacciulli N i sur. Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 2001; 25: 805-10. (Pubitemid 32601372)
24. Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F i sur. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am J Cardiol 2007; 100: 234-39.
25. Szanto I, Kahn CR. Selective interaction between leptin and insulin signaling pathways in a hepatic cell line. Proc Natl Acad Sci U S A 2000; 97: 2355-60. (Pubitemid 30134073)
26. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol 2010; 314: 1-16.
27. Bluher S, Mantzoros CS. Leptin in humans: lessons from translational research. Am J Clin Nutr 2009; 89: 991-7.
28. Giannessi D, Maltinti M, Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res 2007; 56: 459-67. (Pubitemid 350137773)
29. Kiess W, Petzold S, Topfer M i sur. Adipocytes and adipose tissue. Best Pract Res Clin Endocrinol Metab 2008; 22: 135-53. (Pubitemid 351222159)
30. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257:167-75.
31. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81. (Pubitemid 34015133)
32. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 2003; 52: 1355-63. (Pubitemid 36666188)
33. Wang C, Mao X, Wang L i sur. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. J Biol Chem 2007; 282: 7991-6. (Pubitemid 47093602)
34. Maeda N, Shimomura I, Kishida K i sur. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002; 8: 731-7. (Pubitemid 34778727)
35. Yokota T, Oritani K, Takahashi I i sur. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-32. (Pubitemid 30661055)
36. Fasshauer M, Kralisch S, Klier M i sur. Adiponectin gene expression and secretion is inhibited by interleukin- 6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301: 1045-50. (Pubitemid 36279218)
37. Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun 2004; 316: 924-9. (Pubitemid 38368041)
38. Ouchi N, Kihara S, Arita Y i sur. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6. (Pubitemid 30005109)
39. Ouchi N, Kihara S, Arita Y i sur. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63. (Pubitemid 32200177)
40. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-6. (Pubitemid 37377262)
41. Arita Y, Kihara S, Ouchi N i sur. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-8. (Pubitemid 34666104)
42. Kumada M, Kihara S, Ouchi N i sur. Adiponectin specifically increased tissue inhibitor of metalloproteinase- 1 through interleukin-10 expression in human macrophages. Circulation 2004; 109: 2046-9. (Pubitemid 38620209)
43. Arita Y, Kihara S, Ouchi N i sur. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
44. Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond) 2005; 29: 766-71. (Pubitemid 40897012)
45. Maeda N, Takahashi M, Funahashi T i sur. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9. (Pubitemid 33643677)
46. Kwon K, Jung SH, Choi C, Park SH. Reciprocal association between visceral obesity and adiponectin: in healthy premenopausal women. Int J Cardiol 2005; 101: 385-90. (Pubitemid 40719974)
47. Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15. (Pubitemid 38638516)
48. Garg A. Lipodystrophies. Am J Med 2000; 108: 143-52. (Pubitemid 30064425)
49. Harsch IA, Bergmann T, Koebnick C i sur. Adiponectin, resistin and subclinical inflammation-the metabolic burden in Launois Bensaude Syndrome, a rare form of obesity. J Physiol Pharmacol 2007; 58 Suppl 1: 65-76. (Pubitemid 350022259)
50. Hotta K, Funahashi T, Arita Y i sur. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-9. (Pubitemid 30353893)
51. Snijder MB, Heine RJ, Seidell JC i sur. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the hoorn study. Diabetes Care 2006; 29: 2498-2503. (Pubitemid 44912259)
52. Iwashima Y, Katsuya T, Ishikawa K i sur. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-23. (Pubitemid 38691756)
53. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-9. (Pubitemid 34655342)
54. Ryo M, Nakamura T, Kihara S i sur. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68: 975-81. (Pubitemid 39540124)
55. Ohashi K, Ouchi N, Kihara S i sur. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. J Am Coll Cardiol 2004; 43: 1195-1200. (Pubitemid 38452596)
56. Hara K, Matsushita Y, Horikoshi M i sur. A proposal for the cutoff point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. Diabetes Care 2006; 29: 1123-4. (Pubitemid 44115258)
57. Lo J, Dolan SE, Kanter JR i sur. Effects of obesity, body composition, and adiponectin on carotid intimamedia thickness in healthy women. J Clin Endocrinol Metab 2006; 91: 1677-82.
58. Torigoe M, Matsui H, Ogawa Y i sur. Impact of the high-molecular-weight form of adiponectin on endothelial function in healthy young men. Clin Endocrinol (Oxf) 2007; 67: 276-81. (Pubitemid 47076306)
59. Kumada M, Kihara S, Sumitsuji S i sur. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-9. (Pubitemid 36091630)
60. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-7. (Pubitemid 38489895)
61. Satoh H, Nguyen MT, Trujillo M i sur. Adenovirus- mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes 2005; 54: 1304-13. (Pubitemid 40586658)
62. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 2008; 6: 87-102. (Pubitemid 351769254)
63. Itoh M, Suganami T, Satoh N i sur. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27: 1918-25. (Pubitemid 47315642)
64. Steppan CM, Bailey ST, Bhat S i sur. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12. (Pubitemid 32151228)
65. Patel L, Buckels AC, Kinghorn IJ i sur. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-6. (Pubitemid 38375833)
66. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med 2004; 10: 126-7. (Pubitemid 38524875)
67. Yang Q, Graham TE, Mody N i sur. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436:356-62. (Pubitemid 41065039)
68. Graham TE, Yang Q, Bluher M i sur. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354:2552-63.
69. Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS. Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: A three year longitudinal study. Clinical Biochemistry 2008; 41: 1034- 8.
70. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin- 6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-50. (Pubitemid 28496456)
71. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82. (Pubitemid 38535056)
72. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34. (Pubitemid 32656163)
73. Zou C, Shao J. Role of adipocytokines in obesityassociated insulin resistance. J Nutr Biochem 2008; 19: 277-86. (Pubitemid 351503767)
74. Krook A. IL-6 and metabolism-new evidence and new questions. Diabetologia 2008; 51: 1097-9.
75. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91. (Pubitemid 23036092)
76. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 74: 443-77.
77. Cawthorn WP, Sethi JK. TNF-alpha and adipocyte biology. FEBS Lett 2008; 582: 117-31.
78. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-14. (Pubitemid 27446179)
79. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 2001; 104: 517-29. (Pubitemid 32201947)
80. Ryden M, Arner P. Tumour necrosis factor-alpha in human adipose tissue - from signalling mechanisms to clinical implications. J Intern Med 2007; 262: 431-8. (Pubitemid 47404374)
81. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779- 85. (Pubitemid 36792470)
82. Klein J, Perwitz N, Kraus D, Fasshauer M. Adipose tissue as source and target for novel therapies. Trends Endocrinol Metab 2006; 17: 26-32. (Pubitemid 43031381)
83. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008; 9: 1121-8. (Pubitemid 351721750)
84. Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab 2005; 19: 637-47. (Pubitemid 41819223)
85. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93(11 Suppl 1): 64-73.
86. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J Clin Endocrinol Metab 2005; 90: 2282-9. (Pubitemid 40586275)
87. Kanda H, Tateya S, Tamori Y i sur. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505.
88. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 2007; 18: 258-62. (Pubitemid 46743048)
89. Kamei N, Tobe K, Suzuki R i sur. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281: 26602-14. (Pubitemid 44401869)
90. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 2005; 29: 146-50. (Pubitemid 40065478)
91. Mohanty P, Aljada A, Ghanim H i sur. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-35.
92. Schernthaner GH, Kopp HP, Kriwanek S i sur. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant- protein-1 in morbid obesity. Obes Surg 2006; 16: 709-15. (Pubitemid 43874824)
93. Herder C, Muller-Scholze S, Rating P i sur. Systemic monocyte chemoattractant protein-1 concentrations are independent of type 2 diabetes or parameters of obesity: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Eur J Endocrinol 2006; 154: 311-17.
94. Inouye KE, Shi H, Howard JK i sur. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007; 56: 2242-50. (Pubitemid 47358231)